Trastuzumab

Cancer Treatment and Research

Volumn 151, Issue , 2009, Pages 181-196

  Perez, Edith A ^a   Palmieri, Frances M ^b   Brock, Shelly M ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HUMAN; INFECTION; INTERSTITIAL PNEUMONIA; LOADING DRUG DOSE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT OUTCOME; VASCULAR DISEASE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; RECEPTOR, ERBB-2; RESEARCH DESIGN;

EID: 77953673917     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-75115-3_12     Document Type: Review

References (47)

1. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5(1):63-69
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182
3. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707- 712
4. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291(16):1972-1977 (Pubitemid 38544278)
5. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118-145
6. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990;8(1):103-112
7. MussHB, ThorAD, BerryDA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330(18):1260-1266
8. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998;90(18):1361-1370
9. Thomas E, Berner G. Prognostic and predictive implications of HER2 status for breast cancer patients. Eur J Oncol Nursing. 2000;4(Suppl1):10-17
10. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997;151(6):1523-1530
11. Baselga J, Albanell J, Molina MA, Arribas J. Mechanism of action of trastuzumab and scientific update. Semin Oncol. 2001;28(5 Suppl 16):4-11.
12. Albanell J, Codony J, Rovira A, Mellado B, Gascon P. Mechanism of action of anti- HER2 monoclonal antibodies: Scientific update on trastuzumab and 2C4. Adv Exp Med Biol. 2003;532:253-268
13. Marty M, Cognetti F, Maraninchi D, et al. Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: Results of a randomized phase II trial by the M77001 Study Group. J Clin Oncol. 2005;23(19):4265-4274
14. Marty M, Cognetti F, Maraninchi D, et al. Superior long-term survival benefits of trastuzumab plus docetaxel compared to docetaxel alone in patients with HER2-positive metastatic breast cancer: Patients surviving more than 4 years in the M77001 study. Breast Cancer Res Treat. 2006;100(Suppl 1):S103.
15. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792
16. Baselga J, Carbonell X, Castaneda-Soto NJ, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol. 2005;23(10):2162-2171
17. CobleighMA,VogelCL, TripathyD, et al.Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639-2648
18. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719-726
19. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215-1221
20. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684
21. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-1672
22. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol. 2007;25(18S):6S.
23. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet. 2007;369(9555):29-36.
24. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2-positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat. 2005;94(Suppl 1):S5.
25. Clinical Trials website. Maintained by the United States National Institutes of Health: National Library of Medicine. National Library of Medicine. 2007. Available at http:// www.clinicaltrials.gov. Accessed October 2007.
26. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 2004;96(10):739-749
27. Pegram MD, Pienkowski T, Northfelt DW, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst. 2004;96(10):759-769
28. Perez EA, Suman VJ, Rowland KM. Two concurrent phase II trials of paclitaxel/ carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005;6:425-432
29. Robert N, Loesch D, Lindquist D. A randomized, phase II trial of weekly paclitaxel vs. weekly paclitaxel+carboplatin for first-line metastatic breast cancer. Breast Cancer Res Treat. 2003;77:534.
30. Robert N, Leyland-Jones B, Asmar L, et al. Randomised phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival. Proc Am Soc Clin Oncol. 2004;23:20.
31. Rowland KM, Suman VJ, Ingle JN, et al. NCCTG 98-32-52: Randomized phase II trial of weekly versus every 3-week administration of paclitaxel, Carboplatin and trastuzumab in women with HER2 positive metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2003;22:8.
32. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without wrastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26(8):1231-1238
33. Rastogi P, Jeong J, Geyer, et al. CE. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/ cyclophosphamide (AC)!paclitaxel (T) vs. AC!T with trastuzumab (H). J Clin Oncol. 2007;25(18S):513.
34. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23(31):7811-7819
35. Perez EA, Suman VJ, Davidson NE, et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings Part I of II. Vol 23, No. 16S (June 1 Suppl), 2005:556.
36. Slamon D, Eiermann W, Robert N. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2-positive early breast cancer patients: Second interim efficacy analysis. Breast Cancer Res Treat. 2006;100(Suppl 1):52.
37. Halyard MY, Pisansky TM, Solin LJ, et al. Adjuvant radiotherapy and trastuzumab in stage I-IIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831. J Clin Oncol. 2006;24(18S):8S.
38. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809-820
39. Sledge GW, O'Neill A, Thor AD. Adjuvant trastuzumab: Long-term results of E2198. Breast Cancer Res Treat. 2006;100(Suppl 1):S106.
40. NCCNClinical Practice Guidelines in Oncology: Breast cancer. National Comprehensive Cancer Network 2007. Available at http://www.nccn.org/ professionals/physician-gls/ PDF/breast.pdf. Accessed May 2007.
41. Chorn N. Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy. Oncol Nurs Forum. 2006;33(2):265-272
42. Paik S, Kim C, Jeong J. Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31. J Clin Oncol. 2007;25(18S):511.
43. Garrison L, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Am J Clin Oncol. 2007;110:489-498
44. Kurian A, Thompson R, Gaw A, Arai S, Ortiz R, Garber A. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007;25(6):634-641
45. Liberato N, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2007;25(6):625-633
46. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial. J Clin Oncol. 2006;24(19):3032-3038
47. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002;94:852-854